SunTrust Downgrades Tetraphase Pharmaceuticals (TTPH) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts TTPH Hot Sheet
Price: $2.20 --0%
Rating Summary:
6 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 19 | New: 41
Rating Summary:
6 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 19 | New: 41
Join SI Premium – FREE
SunTrust Robinson Humphrey downgraded Tetraphase Pharmaceuticals (NASDAQ: TTPH) from Buy to Neutral with a price target of $12.00 (from $54.00).
For an analyst ratings summary and ratings history on Tetraphase Pharmaceuticals click here. For more ratings news on Tetraphase Pharmaceuticals click here.
Shares of Tetraphase Pharmaceuticals closed at $44.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 1st Source (SRCE) PT Raised to $92 at KBW After a 'High Quality Result'
- Seagate Technology (STX) PT Lowered to $1,100 at Rosenblatt
- Eli Lilly (LLY) PT Raised to $1,450 at Bernstein SocGen on 'International Upside Potential'
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
SunTrust Robinson HumphreySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
